This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Nanotechnology has opened new avenues toward the development of site specific chemotherapy. We are designing nanoparticles that carry either a chemotherapeutic or a contrast agent for magnetic resonance imaging for application in cancer treatment and diagnosis, respectively. Nanometer-sized particles have been shown to selectively accumulate in tumors due to immature, leaky vasculature. Our goal is to augment this selective accumulation by adding a targeting peptide to the nanoparticle surface. Our studies to date have focused on fabricating homogeneous populations of ~50, ~250, and ~500 nm nanoparticles of biodegradable poly(dl-lactic-co-glycolic acid) (PLGA). The cyclic peptide, cLABL, has been proven to bind with high affinity specificity to intracellular cell adhesion molecule-1 (ICAM-1), which is upregulated in lung cancer, pancreatic cancer, prostate cancer, etc. We have tethered cLABL to the surface of PLGA nanoparticles and quantified the surface density by a detecting the presence of the di-sulfide bond on the peptide via a ThioGlo fluorescence assay. To increase the accessibility of cLABL to ICAM-1 on the surface of cells, we have attached carbodiimide or polyethylene glycol spacers to the nanoparticle surface and subsequently reacted cLABL to the distal end of these spacers. In a parallel study, we have partnered with Dr. Mehmet Bilgen at the Hoglund Brain Imaging Center at the University of Kansas Medical Center to test our ability to encapsulate gadolinium into PLGA nanoparticles as an MRI contrast enhancing agent. He has verified the ability of these nanoparticle formulations to enhance magnetic resonance images in a concentration dependent manner. In ongoing studies, we are fabricating fluorescent nanoparticles with and without cLABL attached. These formulations will be incubated with cancerous Caco-2 or endothelial cell monolayers (HUVECs) to quantify the adhesion or endocytosis of cLABL-nanoparticles compared to unlabeled nanoparticles. In parallel, we plan to compare the biodistribution of cLABL-nanoparticles to unlabeled nanoparticles via MRI.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas Lawrence
Schools of Pharmacy
United States
Zip Code
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Ishiguro, Susumu; Kawabata, Atsushi; Zulbaran-Rojas, Alejandro et al. (2018) Co-treatment with a C1B5 peptide of protein kinase C? and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 495:962-968
He, Chenchen; Duan, Shaofeng; Dong, Liang et al. (2017) Characterization of a novel p110?-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate 77:1187-1198
White, Peter T; Subramanian, Chitra; Zhu, Qing et al. (2016) Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery 159:142-51
Ohta, Naomi; Ishiguro, Susumu; Kawabata, Atsushi et al. (2015) Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One 10:e0123756
Li, Benyi; Thrasher, James Brantley; Terranova, Paul (2015) Glycogen synthase kinase-3: a potential preventive target for prostate cancer management. Urol Oncol 33:456-63
Ishiguro, Susumu; Yoshimura, Kiyoshi; Tsunedomi, Ryouichi et al. (2015) Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther 16:307-16
Li, Benyi; Sun, Aijing; Jiang, Wencong et al. (2014) PI-3 kinase p110?: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol 2:188-98
Bibis, Stergios S; Dahlstrom, Kelly; Zhu, Tongtong et al. (2014) Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogs. Mol Biochem Parasitol 196:90-9
Subramanian, Chitra; Zhang, Huaping; Gallagher, Robert et al. (2014) Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas. World J Surg 38:1343-52

Showing the most recent 10 out of 240 publications